MDS expands Taiwan capacity in early stage focus

By Nick Taylor

- Last updated on GMT

Related tags: Mds pharma services, Pharmacokinetics, Pharmacology, Drug discovery

MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.

The overhaul is part of MDS’ increased focus on early stage research, which was demonstrated by the sale of its late stage trial unit to INC research, and is due to be completed in 2010.

MDS’ expansion will double the site’s in vivo ​safety and efficacy testing capacity, with space tailored to an individual client’s needs, and upgrade and expand its molecular screening and profiling services.

This includes the installation of additional robotic high-throughput screening capacity and analytical support, which MDS believes will improve the site’s automated molecular screening and profiling capability and efficiency.

David Spaight, president of MDS Pharma Services, said: "This new and expanded facility will cement our position as the global leader in the discovery pharmacology space, where we are one of the top two providers of molecular screening, and a key supplier of in vivo efficacy and safety testing​.

"This investment builds on a 40-year track record of success in this service area, and supports our recently announced strategic focus on the discovery through Phase IIa proof-of-concept segment of the outsourcing market​."

Early-stage offering

The Taiwan facility forms part of MDS’ Pharmacology/DMPK (drug metabolism and pharmacokinetics) services, which offers molecular, cellular, ADME (absorption, distribution, metabolism, and excretion) and in vivo​ assays.

Clients can use these services to help identify drug candidates, profile for selectivity, assess potential for adverse events, evaluate efficacy and establish proof of concept.

MDS believes that clients using these services can “help speed lead optimization earlier in the discovery phase and streamline the surest path to the clinic​”.

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars